UCL Institute of Neurology


Prof. P. Whiting

Paul Whiting is Chief Scientific Officer of the Alzheimer’s Research UK UCL Drug Discovery Institute (AR-UK UCL DDI).  Established in 2015, its goal is to facilitate the rapid translation of knowledge generated at UCL and partners towards novel therapeutics for neurodegenerative diseases: the dementias, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotropic lateral sclerosis.   The AR-UK UCL DDI will consist of a team of ~ 25 chemists and biologists tasked with the goal of  developing and validating therapeutics for neurodegenerative diseases suitable for progression towards clinical trials.

The Lead Academic Scientists for the Institute are UCL Profs Giampietro Schiavo, John Hardy and Bart de Strooper.

The AR-UK UCL DDI is interested in hearing your ideas regarding new hypotheses and drug targets for therapies for neurodegenerative diseases, and actively seeks opportunities for collaboration.  Please contact p.whiting@ucl.ac.uk

or visit our the Alzhmeier's Research website